Horny Goat Weed (Epimedium) in Viril Edge: What the Research Measured

What the Viril Edge label actually says about horny goat weed

The Viril Edge Supplement Facts panel lists a single “Proprietary Male Support Blend” totaling 838 mg per two-capsule serving (30 servings per 60-capsule bottle). Horny Goat Weed Extract, botanically identified as Epimedium Sagittatum, is printed second in the ingredient list, after Tribulus Terrestris Extract and before Longjack, Ginseng Root, Ashwagandha and Yohimbe extracts. As with every ingredient in this blend, only the combined 838 mg total is disclosed — there is no individual milligram figure for horny goat weed, and critically, no standardization percentage for icariin, the marker compound most commonly used in the scientific literature to characterize how “strong” an Epimedium extract is. Commercial Epimedium extracts on the broader supplement market are frequently sold standardized to a stated icariin percentage (5%, 10%, 20%, and so on); Viril Edge's label states none of this, so the icariin content of this specific product is simply unknown from the label alone.

This matters more for horny goat weed than it might for some other botanicals, because icariin is understood to be the primary bioactive component researchers study when they investigate Epimedium's mechanisms. A product could contain a whole-plant extract with meaningful icariin content, or a weakly processed extract with very little, and an ingredient list that says only “Epimedium Sagittatum” inside an undisclosed blend share cannot distinguish between the two.

What is Epimedium, and where does the “horny goat weed” reputation come from?

Epimedium is a genus of flowering plants used in traditional Chinese medicine for centuries, generally under the name yin yang huo. The common English name “horny goat weed” comes from a folk story about goats becoming more sexually active after grazing on the plant — a colorful origin story, not a scientific finding. Modern pharmacological interest in Epimedium centers on a class of compounds called prenylated flavonoids, of which icariin is the most-studied. Icariin and some of its metabolites have been investigated in laboratory settings for a range of proposed mechanisms, including phosphodiesterase type 5 (PDE5) inhibition — the same general class of mechanism used by prescription erectile-dysfunction medications — along with antioxidant, anti-inflammatory and bone-density-related effects studied in entirely separate contexts (Epimedium is also researched for osteoporosis, unrelated to sexual function).

A recent broad review, “An Overview of the Phytochemistry, Biological Activities and Therapeutic Potential of Epimedium spp.,” published in Plants in 2026 (PMID 42514482), surveys this full range of research and underscores how much of the pharmacological groundwork on Epimedium spans multiple therapeutic areas — bone health, immune modulation, neuroprotection and cardiovascular research among them — with sexual-function research forming only one strand within a much larger phytochemical research program, most of it preclinical.

What icariin research has actually measured

A 2026 review specifically focused on erectile function, “Molecular mechanisms of icariin in the treatment of erectile dysfunction,” published in Sexual Medicine Reviews (PMID 42476543), summarizes the mechanistic case for icariin's effect on erectile tissue. Reviews of this kind synthesize a body of underlying primary research that is overwhelmingly conducted in animal models rather than in human clinical trials. Two representative primary studies illustrate the pattern directly:

A 2025 study in Sexual Medicine (PMID 40161546) examined icariin's effect on penile cavernous tissue in type 1 diabetic rats, reporting that icariin inhibited hyperglycemia-induced cell death in that tissue and improved a measure of erectile function in the animal model. A companion 2025 study in The Journal of Sexual Medicine (PMID 39905744) looked at spontaneously hypertensive rats and found that icariin improved erectile function in that model by downregulating a specific signaling protein (GRK2) in penile cavernous tissue. Both are legitimate, PubMed-indexed, peer-reviewed studies — and both are exactly what they say they are: controlled experiments in rats with a specific induced condition (diabetes, hypertension), measuring tissue-level and biochemical outcomes, not a randomized trial of oral icariin supplementation in men.

This is the core distinction worth holding onto when reading marketing claims built on “clinically studied” icariin: a real, growing body of mechanistic and animal research exists, and it consistently points toward plausible biological activity relevant to erectile tissue. What that body of research has not yet firmly established is the translation step — a defined oral dose of a standardized icariin extract, given to men (healthy or with diagnosed erectile dysfunction), in a randomized placebo-controlled design, measuring a validated outcome like the IIEF questionnaire. Our search of PubMed for controlled human trials of Epimedium specifically for male sexual function returned essentially no matching randomized human trials — the human evidence base, as of this writing, has not caught up with the animal and mechanistic literature.

What has and hasn't been measured, at a glance

Study type	What was measured	Applies directly to a human taking an oral capsule?
Phytochemistry / pharmacology reviews (e.g. PMID 42514482)	Chemical composition, known mechanisms across multiple health areas	Background only — not an outcome study
Mechanistic review of icariin and ED (PMID 42476543)	Synthesis of proposed cellular/molecular pathways	Summarizes preclinical evidence, not a trial result
Diabetic rat study (PMID 40161546)	Cell death and erectile function measures in rat penile tissue	No — animal model of a specific disease state
Hypertensive rat study (PMID 39905744)	Signaling protein (GRK2) and erectile function in rat penile tissue	No — animal model of a specific disease state
Randomized controlled human trial of a defined icariin dose	—	Not identified in our PubMed search

Why the missing standardization number is the crux of the issue

Even setting aside the human-trial gap, the standardization question stands on its own. In the broader supplement market, Epimedium extracts are commonly sold at stated icariin percentages, and researchers designing animal or cell studies typically use a purified or standardized icariin preparation at a known concentration, precisely so the dose delivered to the tissue is measurable and reproducible. A product label that says only “Horny Goat Weed Extract (Epimedium Sagittatum)” inside an undisclosed blend share tells a buyer nothing about where on that spectrum the product sits. It could be a well-standardized extract; it could be a low-icariin leaf preparation; the label simply does not say, and neither the amount nor the standardization can be verified from the packaging, the marketing images, or the independent third-party review that reproduces the same panel we cite in this article.

The 2023 Nutrients meta-analysis by Petre and colleagues on erectile-dysfunction supplements broadly (PMID 37686709), which we also reference in our companion article on tribulus dosing in this same blend, makes a directly applicable point: across the marketed products the authors scored, the large majority combined many active ingredients at doses too low, or too undisclosed, to be confidently matched against any minimal effective dose established in trials. Horny goat weed inside an 838 mg six-ingredient blend is a textbook example of the pattern that review describes.

How this fits with the rest of the Viril Edge blend

Horny goat weed shares its labeling problem with every other botanical in this formula. Our companion piece on tribulus terrestris dosing versus what trials actually show covers the ingredient listed just before it on the panel, where controlled human trials do exist but at doses that, taken alone, already exceed the entire 838 mg blend total. Our review of Panax ginseng evidence for male vitality covers a 2021 Cochrane systematic review of nine human trials, the most rigorous evidence available for any single ingredient in this blend, which still found only a trivial effect on erectile function. And our existing article on tongkat ali and zinc covers the longjack component. Set side by side, horny goat weed is arguably the ingredient in this specific formula with the largest gap between marketing reputation and the maturity of its human evidence base — not because the underlying biology is implausible, but because so little of the published research has yet been done in people rather than in rats or cell cultures.

Safety notes specific to Epimedium and icariin

Because controlled human dosing data is scarce, formal human safety data for isolated icariin or standardized Epimedium extracts is correspondingly limited compared with better-studied single ingredients like zinc. Epimedium has a long history of traditional use, which is a different kind of evidence than a modern safety trial, and traditional-use history does not establish safety at the concentrations found in modern standardized extracts, nor interactions with medications. Because icariin's proposed mechanism overlaps conceptually with PDE5-inhibitor drugs (the class used in prescription ED medication), anyone taking a prescription PDE5 inhibitor, nitrate medication, or blood-pressure medication should discuss any Epimedium-containing supplement with a physician before use, out of caution rather than confirmed evidence of a specific interaction. The Viril Edge label's printed caution applies here as everywhere in the formula: not for pregnant or nursing women, those under 18, or anyone with a known medical condition, without first consulting a physician.

Where the evidence stops

The honest summary of Epimedium and icariin research, as it stands in the PubMed-indexed literature reviewed for this article, is that a substantial and growing mechanistic case exists — built almost entirely on animal models of diabetes, hypertension and nerve injury, plus cell and tissue studies — while confirmatory randomized controlled trials of a defined oral icariin dose in men have not caught up. That gap is not evidence that the ingredient does nothing; it is evidence that the marketing language built around it (“clinically studied,” “proven”) runs ahead of what has actually been measured in people. Layered on top of that evidence gap, Viril Edge's own label does not disclose how much horny goat weed extract, or what icariin content, this specific product contains. Two separate uncertainties — the maturity of the underlying science, and the transparency of this specific label — both point toward the same conclusion: treat marketing claims about this ingredient with more skepticism than the traditional-medicine reputation might suggest.

Frequently asked questions